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OBJECTIVE—Increased plasma levels of free fatty acids occur
in obesity and type 2 diabetes and contribute to the development of
insulin resistance. Saturated fatty acids (SFAs) such as palmitate
especially have lipotoxic effects leading to endoplasmatic reticulum
(ER) stress, inﬂammation, and insulin resistance. Stearoyl-CoA
desaturase 1 (SCD1) plays a key role in preventing lipotoxic effects,
as it converts SFAs to less harmful monounsaturated fatty acids.
Here, we tested the hypothesis that individual differences in the
regulation of SCD1 expression by palmitate exist and inﬂuence
insulin sensitivity and the cellular response to palmitate.
RESEARCH DESIGN AND METHODS—Palmitate-induced
gene expression was studied in primary human myotubes of 39
metabolically characterized individuals, as well as in an SCD1-
overexpressing cell culture model.
RESULTS—SCD1 mRNA expression and inducibility by palmi-
tate in cultured myotubes showed a broad interindividual varia-
tion, presumably due to inheritable characteristics of the donors.
Overexpression of SCD1 prevented the inﬂammatory and ER
stress response to palmitate exposure. In primary human myo-
tubes, high SCD1 inducibility was associated with a low inﬂam-
matory (interleukin [IL]-6, IL-8, and chemokine [CXC motif]
ligand 3 [CXCL3]) and ER stress (CCAAT/enhancer binding
protein [C/EBP] homologous protein, activating transcription
factor 3 [ATF3], and X-box binding protein 1 [XBP1]) response to
palmitate exposure. Finally, palmitate-stimulated SCD1 mRNA
expression, positively correlated with intramyocellular lipid
(IMCL) content of the donors, was measured by
1H-magnetic
resonance spectroscopy. After adjustment for IMCL, SCD1 ex-
pression and inducibility were positively correlated with insulin
sensitivity.
CONCLUSIONS—We hypothesize that myocellular SCD1 in-
ducibility by palmitate is an individual characteristic that modu-
lates lipid storage, palmitate-induced inﬂammation, ER stress,
and insulin resistance. This may describe individuals with in-
creased capability of innoxious free fatty acid handling and
benign triglyceride storage. Diabetes 58:1757–1765, 2009
D
iabetes and the metabolic syndrome represent
an increasing problem worldwide. In obesity
and type 2 diabetes, elevated plasma concentra-
tions of nonesteriﬁed free fatty acids (FFAs)
are observed (1,2). The increased release of FFAs from the
adipose tissue is an important factor modulating insulin
sensitivity. Insulin resistance can develop within hours of
an acute elevation of plasma FFA levels in humans (2,3).
Proposed mechanisms leading to FFA-induced insulin
resistance are summarized under the concept of lipotox-
icity. Lipotoxicity involves an increase of intracellular
fatty acid metabolites such as diacylglycerol and cer-
amides, leading to endoplasmic reticulum (ER) stress and
serine/threonine phosphorylation of insulin receptor sub-
strates and the activation of nuclear factor (NF)-B sig-
naling pathways (1). A consecutive acute inﬂammatory
response with secretion of cytokines and diminished
events downstream of insulin receptor signaling cascade
leads to a low-grade inﬂammatory state associated with
insulin resistance.
The saturated fatty acids (SFAs) stearate and palmitate
especially have a strong lipotoxic potential to induce
inﬂammation, ER stress, and insulin resistance (4–8). The
microsomal enzyme stearoyl-CoA desaturase 1 (SCD1)
plays a key role in modulating these effects of SFAs
(8–11). SCD1 desaturates stearate and palmitate to gener-
ate the less toxic monounsaturated fatty acids (MUFAs)
oleate and palmitoleate. SCD1 activity is subject to a
complex and tight regulation by hormonal and nutrient
stimuli on the transcriptional level (10,12–14). While poly-
unsaturated fatty acids and fasting strongly suppress SCD1
expression, insulin, glucose, and SFAs potently stimulate
SCD1 expression on a transcriptional level. Overexpres-
sion of SCD1 promotes triglyceride storage and reduces
palmitate-induced apoptosis and ceramide and diacylglyc-
erol synthesis, as well as insulin resistance (9–11). In vivo,
increased skeletal muscle SCD1 expression is observed in
conditions with elevated plasma FFA levels like obesity or
after physical exercise (9,15–17). As SCD1 activity pre-
vents lipotoxicity in cell culture models (9–11), upregu-
lated SCD1 expression in response to the SFA palmitate
could be an endogenous protective mechanism to amelio-
rate its deleterious effects. In the present study, we tested
the hypothesis that interindividual differences in upregu-
lation of SCD1 expression in response to palmitate expo-
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humans. Therefore, we studied individual palmitate-in-
duced SCD1 gene expression in primary human myotubes
of 39 metabolically characterized individuals and studied
the relation with intramyocellular lipid (IMCL) content
and insulin sensitivity. Furthermore, we evaluated the
effect of individual SCD1 expression on markers of inﬂam-
mation and ER stress.
RESEARCH DESIGN AND METHODS
A total of 39 individuals were studied. These subjects were healthy nondia-
betic participants of the Tu ¨bingen Family Study for Type 2 Diabetes (TU ¨ F
study) and gave informed written consent to the study. Individuals were
recruited from the southern part of Germany and were not related to each
other. The participants did not take any medication known to affect glucose
tolerance or insulin sensitivity. The ethical committee of the Tu ¨bingen
University Medical Department had approved the protocol.
Determination of blood parameters. Plasma glucose was determined using
a bedside glucose analyzer (glucose oxidase method; Yellow Springs
Instruments, Yellow Springs, OH). Serum FFA concentrations were mea-
sured with an enzymatic method (Wako Chemicals, Neuss, Germany).
Plasma triglycerides, total cholesterol, and HDL and LDL cholesterol were
measured using the ADVIA 1650 clinical chemical analyzer, and insulin was
analyzed using the ADVIA Centaur immunoassay system according to the
instructions of the manufacturers. Both analyzers were from Siemens
Medical Solutions (Fernwald, Germany).
Insulin sensitivity. After a 10-h overnight fast, all subjects underwent a 75-g
oral glucose tolerance test, as previously described (18,19).
Determination of IMCL by magnetic resonance spectroscopy. Neutral
lipids within the muscle cell (IMCL) and those interlaced between the muscle
ﬁbers can be differentiated due to their geometrical arrangement using proton
magnetic resonance spectroscopy. Localized image-guided proton spectra of
the tibialis anterior muscle were acquired on a 1.5-Tesla whole-body imager
(Magnetom Vision; Siemens, Erlangen, Germany). For volume selection, a
single-voxel STEAM technique was applied. Measurement parameters were
echo time, 10 msec; repetition time, 2 s; volume of interest, 11  11  20 mm
3;
and 40 acquisitions. IMCL in the tibialis muscle were quantiﬁed as previously
described (20).
Body composition. Total body fat and lean body mass were measured by
bioelectrical impedance (RJL, Detroit, MI).
Measurement of VO2max. The individuals underwent a continuous, incremen-
tal exercise test to volitional exhaustion using a cycle ergometer. The cycle
ergometer test was performed on an electromagnetically braked cycle er-
gometer (Ergometrics 800 S; Ergoline, Bitz, Germany). Oxygen uptake was
measured using a spiroergometer (MedGraphics System Breese Ex 3.02 A;
MedGraphics, St. Paul, MN). Maximal aerobic capacity was expressed as VO2
(milliliters per minute) per kilogram lean body mass.
Preparation of BSA bound FFAs. In most experiments, cells were incu-
bated with the FFAs palmitate or oleate. FFAs were bound to fatty acid–free
albumin solution from bovine serum fraction V 10% in sterile ﬁltered Dulbec-
co’s PBS (Sigma-Aldrich, Taufkirchen, Germany). In brief, FFAs (200 mmol/l
in ethanol) were diluted in the BSA solution to a concentration of 6 mmol/l
(the FFA-to-BSA ratio was 4 to 1 mol to mol). This mixture was gently agitated
at 37°C under nitrogen overnight. These stock solutions were stored in
aliquots under nitrogen at 20°C.
Cell culture. Primary human skeletal muscle cells were obtained from needle
biopsies of the vastus lateralis muscle. The primary skeletal muscle cells were
grown and differentiated as previously described (21). When myoblasts
reached 80–90% conﬂuence, the cells were fused for 4 days in -minimum
Eagle’s medium containing 5.5 mmol/l glucose with 0.2% antibiotic antimy-
cotic solution (Invitrogen) and 2% fetal bovine serum (fusion medium). On day
5, myotubes were stimulated with FFAs (0.5 mmol/l) or BSA for 20 h in fusion
medium. Human embryonic kidney (HEK) 293 cells were stably transfected
with a hemagglutinin (HA)-tagged human SCD1 expression vector (10) or the
empty control vector pCDNA3 and cultured in DMEM (BioWhittaker, Verviers,
Belgium) containing nonessential amino acids supplemented with 2 mmol/l
glutamine, 1 mmol/l pyruvate, 100 units/ml penicillin, 0.1 mg/ml streptomycin,
0.5 mg/ml geneticin, and 10% FCS.
Cell viability assay. The water soluble tetrazolium (WST)-1 viability assay
(Roche Molecular Biochemicals, Mannheim, Germany) was used to determine
HEK293 cell survival after palmitate exposure according to the manufacturer’s
instructions. The amount of formazan dye formed directly correlates to the
number of metabolically active and viable cells in the culture. A total of 3,000
cells were seeded per well in 96-well plates the day before treatment. Cell
viability was analyzed 48 h after addition of BSA or palmitate (0.6 mmol/l).
BSA-treated cells were set as 100% viability, and cell survival (%) was
determined by averaging four repeated experiments performed in
quadruplicate.
Real-time RT-PCR. Cells were treated for 20 h, subsequently washed, and
harvested. RNA was isolated with RNeasy columns (Qiagen, Hilden, Ger-
many). Quality and quantity of total RNA was assessed spectrophotometri-
cally. Total RNA treated with RNase-free DNase I was transcribed into cDNA
using AMV reverse transcriptase and the ﬁrst-strand cDNA kit from Roche
Diagnostics (Mannheim, Germany). Quantitative PCR was performed at least
in duplicate with SYBR Green on a LightCycler (Roche Diagnostics).
Conditions for RT-PCR quantiﬁcation of mRNAs. The conditions for
RT-PCR quantiﬁcation of mRNAs were as follows: hSCD1 5-TGCAGGAC-
GATATCTCTAGC-3,5 -ACGATGAGCTCCTGCTGTTA-3, T 58°C, 45 cycles, 3
mmol/l MgCl2; interleukin (IL)-8 5-AAGAAACCACCGGAAGGAAC-3,5 -ACT-
TCTCCACAACCCTCTGC-3, T 68°C, 45 cycles, 3 mmol/l MgCl2; IL-6 5-
CCAGCTATGAACTCCTTCTC-3,5 -GCTTGTTCCTCACATCTCTC-3, T 63°C,
45 cycles, 3 mmol/l MgCl2; chemokine (CXC motif) ligand 3 (CXCL3) 5-
CTGCCCTTACCAGAGCTGAA-3,5 -TCCCCACCCTGTCATTTA TC-3, Tan
61°C, 45 cycles, 4 mmol/l MgCl2; and XPB1s 5-CCGCAGCAGGTGCAGG-3,
5-GGGGCTTGGTATATATGTGG-3, T 66°C, 3 mmol/l MgCl2 (22).
QuantiTect primer assays. Activating transcription factor 3 (ATF3),
CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP),
and X-box binding protein 1 (XBP1) RT-PCRs were performed using a
QuantiTect SYBR Green PCR Kit and Quantitect Primer Assays
Hs_ATF3_1_SG QT00000273, Hs_DDIT3_1_SG (QT00082278), and
Hs_XBP1_1_SG (QT00068383) according to the manufacturers instructions
(Qiagen, Hilden, Germany) on a Roche LightCycler 480 (Mannheim,
Germany).
Cellular fatty acid composition. The total cellular fatty acids were sub-
jected to direct transesteriﬁcation. The quantiﬁcation of the fatty acid methyl
ester composition was analyzed using gas chromatography with a ﬂame
ionization detector (7890A GC system; Agilent Technologies, Waldbronn,
Germany) on a 60 m  0.25 mm  0.2 m fused silica column (Rtx 2330;
Rystek) as previously described (10).
Western blotting. Cytosolic cell extracts were separated by SDS-PAGE, and
proteins were transferred to a nitrocellulose membrane by semidry electrob-
lotting. Immunodetection was performed using a mouse monoclonal antibody
against the full-length recombinant human hSCD1 (ab19862) (Abcam, Cam-
bridge, U.K.) and the cytosolic protein glutamine:fructose-6-phosphate ami-
notransferase (23).
Calculations and statistics. Insulin sensitivity was estimated from the oral
glucose tolerance test (in arbitrary units) as proposed by Matsuda and
DeFronzo (24) [10,000/(Glc0  Ins0  Glcmean  Insmean)
1/2]. P values were
determined by Student’s t test on log-transformed data of non–normally
distributed parameters. To adjust insulin sensitivity for the independent
effects of IMCL or BMI, we performed multivariate regression analysis. The
statistical software package JMP 4.0 (SAS Institute, Cary, NC) was used.
RESULTS
First, we examined the effect of palmitate exposure on
SCD1 mRNA expression in primary myotubes of 39 do-
nors. The anthropometric and metabolic characteristics of
the myotube donors are displayed in Table 1. On average,
we observed a doubling of SCD1 mRNA expression after
palmitate exposure (0.5 mmol/l, 20 h). However, basal
SCD1 mRNA expression levels, as well as the upregulation
of SCD1 mRNA expression in response to palmitate,
showed a remarkable interindividual variation. In myo-
tubes of three donors, the SCD1 expression was reduced,
while most others showed a strong but variable increase
(0.46- to 4.38-fold) (Fig. 1A and B).
Next, we established a cell culture model to study the
role of SCD1 in fatty acid–induced inﬂammation and ER
stress. We generated a cell line with stable overexpression
of HA-tagged human SCD1 in HEK293 cells. In the Western
blot, overexpressed SCD1-HA can be detected above the
endogenous SCD1 protein due to the added HA tag (Fig.
2A). Fatty acid analysis revealed a signiﬁcantly higher
proportion of the MUFA (C16:1) and the SCD1 product-to-
substrate ratio (C16:1/C16:0) in SCD1-overexpressing cells
compared with controls (Fig. 2B). As overexpression of
SCD1 has been shown to prevent lipotoxicity (10,11), the
SCD1, ER STRESS, AND IMCL
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WST-1 assay (42%, P  0.007) after extended exposure to
palmitate (0.6 mmol/l, 48 h). These results indicate a
detoxifying effect of overexpressed SCD1 in our cell
model.
After having characterized the SCD1 cell line, we deter-
mined the induction of inﬂammatory cytokines and key ER
stress markers upon palmitate and oleate exposure (0.5
mmol/l, 20 h). Palmitate strongly induced the mRNA
expression of the inﬂammatory cytokines IL-8 (17-fold)
and CXCL3 (3.6-fold) in control cells but not in SCD1-
overexpressing cells (Fig. 3A and B). Oleate, a MUFA and
a product of SCD1 action, did not induce these inﬂamma-
tory cytokines. IL-6 mRNA was below detection limits in
these cells by RT-PCR. Next, we investigated palmitate-
induced ER stress, which is a potential molecular link
between obesity, elevated FFAs, insulin resistance, and
the progression to diabetes (1). The ER stress markers
CHOP, ATF3, XBP1, and the spliced form XBP1s were also
signiﬁcantly induced after palmitate exposure (Fig. 3C–F).
In contrast, oleate did not induce expression of the ER
stress markers. The induction of inﬂammatory and ER
stress markers IL-8, CXCL3, ATF3, XBP1, and XBP1s was
almost completely prevented in SCD1-overexpressing cells
(Fig. 3A–F). These experiments demonstrate that SCD1
overexpression can prevent palmitate-induced inﬂamma-
tory response, ER stress, and lipotoxicity.
Following this, we aimed to validate these ﬁndings in
our set of primary human myotubes. We tested the hypoth-
TABLE 1
Anthropometric and metabolic data from myotube donors and the subgroup with available data on IMCLs
Demographics and body
composition All participants Participants with IMCL data
Sex (female/male) 18/21 10/18
Age (years) 26 	 5 (19–36) 27 	 4 (22–35)
BMI (kg/m
2) 23.3 	 3.5 (18.3–35.7) 22.8 	 2.8 (18.3–29.1)
Body fatbioimpedance (%) 21.9 	 8.1 (7–39) 19.7 	 7.6 (7–37)
Waist-to-hip ratio 0.81 	 0.08 (0.7–1) 0.81 	 0.08 (0.7–1)
SCD1 induction by palmitate (fold) 1.95 	 0.91 (0.46–4.38) 1.96 	 0.86 (0.53–4.38)
IMCLMRS (AU) 3.4 	 1.7 (0.5–7.8)
Metabolic characteristics
Fasting glucose (mmol/l) 4.8 	 0.43 (3.8–5.4) 4.7 	 0.41 (3.9–5.4)
2-h glucose (mmol/l) 5.27 	 1.1 (3.5–7.4) 5.17 	 1.1 (3.5–7.1)
Fasting insulin (pmol/l) 38.3 	 20 (13–103) 38.2 	 19 (13–79)
2-h insulin (pmol/l) 189.9 	 114 (60–524) 189.9 	 111 (60–491)
Fasting serum FFAs (mol/l) 408 	 167 (140–808) 414 	 179 (163–808)
Fasting triglycerides (mg/dl) 88.9 	 37 (34–186) 83.8 	 32 (43–186)
Fasting total cholesterol (mg/dl) 183 	 38 (119–299) 182 	 40 (123–299)
Fasting HDL cholesterol (mg/dl) 56.1 	 15 (37–96) 57.1 	 14 (38–96)
Fasting LDL cholesterol (mg/dl) 114.3 	 33 (63–207) 113.6 	 34 (63–207)
Vo2Max (ml  min
1  kg lbm
1) 41.8 	 15 (22.3–95.6)
ISIOGTT (AU) 26.2 	 10.9 (6.5–47) 25.9 	 10.9 (6.5–47)
Data are means 	 SE (range). ISIOGTT, insulin sensitivity estimated from the OGTT; lbm, lean body mass; MRS, magnetic resonance imaging;
OGTT, oral glucose tolerance test.
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FIG. 1. SCD1 mRNA expression is stimulated by the saturated fatty
acid palmitate. A: Change in SCD1 mRNA expression in primary human
myotubes of 39 donors is displayed after 20 h exposure to 0.5 mmol/l
palmitate or the BSA control. B: Fold changes of SCD1 expression after
palmitate exposure are displayed. The induction of SCD1 expression
ranges from 0.46- to 4.38-fold. SCD1 mRNA expression is stimulated
1.95-fold by palmitate exposure. *P < 0.0001 (signiﬁcantly different).
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FIG. 2. Characterization of an SCD1 overexpression model in HEK293
cells. HEK293 cells were stably transfected with HA-tagged human
SCD1. A: Endogenous SCD1 and overexpressed SCD1-HA protein
expression is visualized by Western blotting using an anti–human-
SCD1 antibody. The strongly overexpressed SCD1-HA is visible above
the endogenous SCD1. The cytosolic protein glutamine:fructose-6-
phosphate aminotransferase was used as a loading control. B: Analysis
of the cellular fatty acid composition revealed a signiﬁcantly higher
fatty acid ratio of SCD1 product to substrate (C16:1/C16:0) in SCD1
than in control cells. Means  SE of n  4 are displayed. *Signiﬁcantly
different between the groups, P < 0.01.
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DIABETES, VOL. 58, AUGUST 2009 1759esis that interindividual differences in SCD1 gene expres-
sion modulate cellular effects of palmitate exposure, such
as induction of inﬂammation and ER stress. Therefore,
myotube donors were divided in a low and a high SCD1
group according to the mean SCD1 inducibility by palmi-
tate in the differentiated myotube cell cultures (Fig. 1). The
two donor groups did not differ in age, BMI, waist-to-hip
ratio, body fat %, VO2max, fasting triglycerides and FFA
levels, or insulin sensitivity (data not shown).
Exposure to palmitate caused a strong induction of
inﬂammatory cytokines IL-6 (13-fold), IL-8 (12-fold), and
CXCL3/macrophage inﬂammatory protein (MIP)-1
 (17-
fold) mRNA expression in human myotubes of all donors.
The induction of all three inﬂammatory cytokines upon
palmitate exposure was signiﬁcantly lower in the high
SCD1 group compared with the low SCD1 group (Fig.
4A–C). This further indicates that high individual induc-
ibility of SCD1 reduces the cellular inﬂammatory response
to palmitate.
Next, we investigated the expression of palmitate-
induced ER stress markers. Palmitate exposure induced
the expression of key ER stress markers CHOP (4.7-fold)
and ATF3 (5.3-fold) in myotubes of all donors. XBP1 and
the activated spliced form XBP1s (not shown) showed a
less pronounced induction (1.7- and 1.6-fold, respectively).
We could demonstrate that the induction of CHOP and
ATF3 was signiﬁcantly reduced in the high-SCD1 group
(Fig. 4D and E). XBP1 also tended to have a less pro-
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FIG. 3. Overexpression of SCD1 prevents palmitate-induced inﬂammatory cytokine induction and ER stress. The expression of inﬂammatory
cytokines (A and B) and ER stress response markers (C–F) in response to palmitate or oleate (0.5 mmol/l; 20 h). Exposure in SCD1 cells and
control cells is displayed. Palmitate, but not oleate, induces the expression of inﬂammatory cytokines. Overexpression of SCD1 almost
completely prevents the induction of IL-8 and CXCL3 by palmitate. The ER stress response markers ATF3, CHOP, XBP1, and the spliced form
XBP1s are increased by palmitate, but not oleate, exposure. Overexpression of SCD1 almost completely prevents the induction of ATF3, CHOP,
XBP1, and the spliced form XBP1s by palmitate. Means  SE of n  6 are displayed. *Signiﬁcantly different palmitate vs. BSA exposure, P < 0.05;
**P < 0.001; #Signiﬁcantly different SCD1 vs. control cells, P < 0.001. , control; u, SCD1.
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1760 DIABETES, VOL. 58, AUGUST 2009nounced increase in the high-SCD1 group, although it did
not reach signiﬁcance (Fig. 4F). These results demonstrate
that high individual inducibility of SCD1 mRNA reduces
palmitate-induced ER stress and further support that the
individual inducibility of SCD1 is an important factor to
prevent lipotoxic effects of palmitate. Following this, we
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FIG. 4. High inducibility of SCD1 is associated with a low inﬂammatory and ER stress response to palmitate in human myotubes. Myotube donors
were divided by the mean of SCD1 induction by palmitate into a group with low () and high (u) inducibility of SCD1. Induction of inﬂammatory
cytokines IL-6, IL-8, and CXCL3/MIP-1 by palmitate was compared between the low and high SCD1 group. The high SCD1 group had signiﬁcantly
lower induction of inﬂammatory cytokines IL-6 (15.7- vs. 8.9-fold, P  0.01) (A), IL-8 (15.0- vs. 9.9-fold, P  0.03) (B), and CXCL3 (20.0- vs.
11.4-fold, P  0.003) (C). The induction of key ER stress markers by palmitate was also compared between the low and high SCD1 group. The
high SCD1 group had signiﬁcantly lower induction of CHOP (5.53- vs. 3.99-fold, P  0.04) (D) and ATF3 (6.02- vs. 4.05-fold, P  0.02) (E) and
tended to lower induction of XBP1 (1.86- vs. 1.52-fold, P  0.13) (F).
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expression in vitro describes an individual characteristic
that also inﬂuences lipid metabolism in vivo.
As the mechanism of how SCD1 prevents lipotoxicity
involves triglyceride storage (11), we investigated the
relation between SCD1 mRNA induction in myotubes with
IMCL levels and insulin sensitivity of the donors in vivo.
IMCL levels were assessed by noninvasive
1H-magnetic
resonance spectroscopy in a subgroup of 28 subjects.
SCD1 inducibility (R  0.54, P  0.003, adjusted for BMI)
(Fig. 5A) as well as palmitate-stimulated SCD1 mRNA
expression levels (R  0.42, P  0.03, not shown) deter-
mined in in vitro–differentiated myotubes was positively
correlated with IMCL levels in the tibialis muscle of the
myotube donors. This demonstrates an in vivo relevance
of individual SCD1 gene expression for skeletal muscle
lipid storage. No correlation between the donors’ BMI,
waist-to-hip ratio, or plasma lipid levels and SCD1 expres-
sion in vitro was observed. As reported previously in
multiple studies (25,26), higher IMCL levels are correlated
with insulin resistance in this group (R  0.45, P  0.015)
(Fig. 5B). However, insulin sensitivity was not correlated
with SCD1 expression or inducibility (R  0.08, P  0.64;
R  0.10, P  0.71, respectively, not shown). To investi-
gate the inﬂuence of SCD1 expression on insulin sensitiv-
ity independent of IMCLs we also performed this analysis
after adjustment for IMCLs. Insulin sensitivity was posi-
tively correlated with SCD1 inducibility (R  0.38, P 
0.047) (Fig. 5C) as well as SCD1 expression levels after
palmitate stimulation (R  0.41, P  0.03) (Fig. 5D). Thus,
SCD1 inducibility might have beneﬁcial effects for the
maintenance of insulin sensitivity.
DISCUSSION
SCD1 is a key regulator in lipid metabolism and modulates
cellular effects of SFAs. In the present study, we could
show that interindividual differences of SCD1 inducibility
by palmitate exist in human myotubes. After the extended
culture protocol of myoblast isolation and myotube differ-
entiation, environmental and humoral factors from the
donors are a priori excluded. Therefore, differences in
SCD1 gene expression or regulation are most likely due to
the donors’ genetic or epigenetic characteristics (15,21),
which can inﬂuence both gene expression in cell culture
and skeletal muscle lipid metabolism in vivo. The molec-
ular mechanism of how SFAs induce SCD1 expression is
not fully understood but may involve activation of NF-B
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FIG. 5. Relationship between SCD1 expression in vitro, the donors’ IMCL levels, and insulin sensitivity. A: The relative increase of SCD1 mRNA
expression in response to palmitate exposure is positively correlated with the donors’ IMCL (n  28, adjusted for BMI). B: Relationship between
IMCL and insulin sensitivity, estimated from the OGTT (24). In the studied population, insulin sensitivity was negatively correlated with IMCL
adjusted for BMI. C and D: Relationship between insulin sensitivity and SCD1 expression cultured myotubes. The relative induction of SCD1
mRNA expression by palmitate (C) as well as absolute SCD1 mRNA expression levels after palmitate exposure (D) was positively correlated with
the donors’ insulin sensitivity after adjustment for IMCL.
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ing to NF-B–responsive elements in the SCD1 promoter
as well as fatty acid upregulation of peroxisome proliferator–
activated receptor- coactivator 1
 and subsequent coac-
tivation of sterol regulatory element–binding protein-1c
(14,27–29). In the present study, we show that SCD1
inducibility displays an immense interindividual variation
and is a determinant of the individuals’ lipid metabolism.
We hypothesized that upregulation of SCD1 expression in
response to palmitate exposure represents a protective
mechanism against lipotoxicity, and individual differences
could inﬂuence the susceptibility for deleterious effects of
SFAs.
Palmitate exposure induced an inﬂammatory response
in primary human skeletal muscle cells as well as in HEK
cells. In our experiments, overexpression of SCD1 in HEK
cells completely prevented the inﬂammatory response to
palmitate exposure. Consistently, we could show that high
SCD1 inducibility is associated with low inﬂammatory
response to palmitate exposure and is associated with
reduced expression of the inﬂammatory cytokines IL-6,
IL-8, and CXCL3 in human myotubes. Murine data support
the protective role of SCD1 in lipid-induced inﬂammation
(14,30). SCD1 knockout mice on a MUFA-depleted diet
display an inﬂammatory and ER stress gene expression
proﬁle (30). Increased levels of ceramides, which are
involved in lipotoxicity and insulin resistance, are ob-
served in hepatic SCD1 knockout mice on a MUFA-free
diet (31). Additionally, SCD1 has been linked to inﬂamma-
tion, as downregulation of hepatic SCD1 exacerbates
inﬂammation and acute colitis (32) and absence of SCD1
promotes inﬂammation and atherosclerosis in a mouse
model of familial hypercholesterolemia (33).
The second deleterious effect of palmitate on human
skeletal muscle cells is the induction of ER stress, which is
discussed as a molecular link between obesity, elevated
FFAs, and insulin resistance (1,3,22). ER stress describes
the accumulation of misfolded proteins that aggregate in
the ER. ER stress activates the unfolded protein response
pathways in order to restore ER homeostasis, reduce ER
stress, and circumvent cell death. These responses include
the splicing of XBP1 mRNA as well as increased XBP1
mRNA transcription and the activation of the PKR-like ER
kinase (PERK)/ATF4 pathway that ﬁnally leads to the
transcriptional activation of the C/EBP homologous pro-
tein CHOP and ATF3. Therefore, increasing mRNA levels
of XBP1s, XBP1, CHOP, and ATF3 represent markers of
ER stress in mammalian cells (1,22).
In human myotubes, palmitate induced increased mRNA
expression levels of ATF3, CHOP, XBP1, and activated,
spliced XBP1s. We could demonstrate that the induction
of ER stress markers was completely prevented by SCD1
overexpression in HEK cells, and high SCD1 inducibility in
myotubes was associated with reduced ER stress re-
sponse. Loss of SCD1 has been shown to increase ER
stress (8,30). In several animal models, induction of ER
stress is associated with insulin resistance, and chaper-
ones that reduce ER stress have been shown to restore
insulin signaling (1,34–37).
As inﬂammation and ER stress can both be a cause of
insulin resistance (1,3) and SCD1 overexpression in skel-
etal muscle cells prevents palmitate-induced insulin resis-
tance (9), it is suggestive to also expect a protective effect
of SCD1 inducibility against insulin resistance in vivo.
However, at ﬁrst, we could not detect an association of
SCD1 induction with insulin resistance. SCD1 inducibility
by palmitate in myotubes was positively correlated with
the donors’ IMCL content in vivo. This association is well
in line with mouse and molecular in vitro data showing
that SCD1 is essential for triglyceride synthesis and stor-
age (29,38,39). In fact, triglyceride synthesis has been
implicated as the crucial mechanism to prevent lipotoxic-
ity (11).
However, multiple studies (25,26) have identiﬁed high
IMCL as an indicator of insulin resistance in humans. This
correlation only exists in lean, sedentary young adults
(25,26), like the group described here, but is lost if a
general population is studied. In fact, in physically trained
subjects, high IMCL is even associated with improved
insulin sensitivity (20,40). It is therefore an unsolved
question as to whether a causal direct relation between
IMCL and insulin resistance exists at all or if both are just
parallel consequences of altered skeletal muscle lipid
metabolism (41). Based on our data, we speculate that
triglyceride storage, as well as inﬂammation, ER stress,
and insulin resistance, may be the common consequence
of an increased fatty acid ﬂux into the skeletal muscle cell.
Furthermore, high SCD1 activity may funnel fatty acids
away from deleterious events toward efﬁcient and innox-
ious triglyceride storage and prevent insulin resistance.
After adjustment for IMCLs, when comparing individuals
with equal IMCL levels, SCD1 induction and palmitate-
induced SCD1 expression levels were positively related
with insulin sensitivity. These ﬁndings imply that high
inducibility of SCD1 by palmitate facilitates benign triglyc-
eride storage in human skeletal muscle, which does not
lead to inﬂammation, ER stress, and insulin resistance.
High SCD1 activity may therefore be a factor that dissoci-
ates benign from malign IMCL storage, a concept that has
recently been suggested for human obesity (19).
Conﬂicting data on the role of SCD1 in mediating insulin
sensitivity exist from cell culture models and SCD1-deﬁ-
cient mice. SCD1-deﬁcient mice are protected from diet-
induced insulin resistance and obesity and have increased
lipid oxidation and thermogenesis (14). However, it re-
mains controversial which organ’s SCD1 activity (liver,
skeletal muscle, or skin) has the major effect for this
phenotype of the whole-body SCD1-deﬁcient mice, since
liver-speciﬁc knockout mice are not protected from high-
fat diet–induced obesity and insulin resistance (31,42). It
has been suggested that elevated activity of SCD1 parti-
tions fatty acids away from oxidation toward storage of
triglycerides (15), a hypothesis that is largely supported by
the data presented in this study. Increasing 
-oxidation via
activation of AMP-activated protein kinase (AMPK) has
been implicated as an alternative way of triglyceride
storage of innoxious fatty acid handling and preventing
lipotoxicity (8,43,44). This pathway, activated by exercise
or antidiabetes drugs like metformin, has been shown to
reduce palmitate as well as cytokine-induced transactiva-
tion of NF-kB and vascular inﬂammation in endothelial
cells (43). Activation of AMPK was therefore proposed as
a target to reduce lipotoxicity and insulin resistance
(44,45). As AMPK was found to be activated in multiple
tissues of SCD1-deﬁcient mice (46,47), this may be a
compensatory mechanism to prevent lipotoxicity and in-
sulin resistance in the absence of SCD1.
In conclusion, we could show that upregulation of SCD1
in response to palmitate has an interindividual variability
that is retained in cultured human myotubes and is asso-
ciated with IMCL content and insulin sensitivity in vivo.
High SCD1 inducibility represents a protective mechanism
A. PETER AND ASSOCIATES
DIABETES, VOL. 58, AUGUST 2009 1763against lipotoxicity and reduces the susceptibility of myo-
tubes toward ER stress and inﬂammation upon palmitate
exposure. This may describe individuals with increased
capability of innoxious FFA handling and triglyceride
storage.
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